tbuckley/cabot-search huggingface dataset:
Escalation of Commitment in Treatment Decisions Near the End of Life
Authors: Laurent Knoops, Philippe Bastin
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells
Authors: Louise Roulin, Ashfaq Ali, Aline Masse, Marie-Magdelaine Coudé, Dominique Bluteau, Thorsten Braun, Jeannig Berrou, Olivier Bluteau, Marc Delord, Maria Eugenia Riveiro, Patrice EDOUARD Herait, Jean Soulier, André Baruchel, Claude Gardin, Hervé Dombret, Raphaël Itzykson
Journal: Blood (2015)
Variable Number of Tandem Repeat (VNTR) Disparity between Donor and Recipient Has Potential To Predict Outcomes of HLA-Identical Allogeneic Stem Cell Transplantation.
Authors: Dong Hwan Kim, Hee Doo Jung, Nan Young Lee, Joon Ho Moon, Sang Kyun Sohn, Jang Soo Suh, Kyu Bo Lee
Journal: Blood (2005)
This is my house – respect it
Authors: Kaustubh G Joshi
Journal: BMJ (2017)

My first day working in the prison was an eye opening experience. I had never previously worked in an environment that was enclosed by high barbed wire fences, surrounded by watchtowers, and patrolled by armed officers. As I entered the medical clinic, I stepped in an unknown fluid, uttered an expletive, and said, “This place sucks.” In the hallway, sitting on a chair, …
Adoptive T Cell Therapy Using Educated T Cells Generated by the Sequential Stimulation with DC/Tumor Fusion Cells and Anti-CD3CD28
Authors: Jacalyn Rosenblatt, Baldev Vasir, Zekui Wu, Corrine Zarwan, Richard Stone, Adam Bissonnette, Thea M Friedman, Donna Neuberg, Natalya Rozenveyn, Brett Glotzbecker, James D. Levine, Robin Joyce, Vassiliki Boussiotis, Dimitrios Tzachanis, Dimitrios Spentzos, Panagiotis Konstantinopoulos, Donald Kufe, David Avigan
Journal: Blood (2008)
Minimal Reduction of PU.1 Is Sufficient to Induce a Preleukemic State and Promote Development of Acute Myeloid Leukemia
Authors: Britta Will, Thomas O. Vogler, Swathi-rao Narayanagari, Boris Bartholdy, Tihomira I. Todorova, Jiahao Chen, Yiting Yu, Jillian Mayer, Mariana da Silva Ferreira, Laura Barreyro, Luis Carvajal, Michael Roth, Johanna van Oers, Sonja Schaetzlein, Christine McMahon, Winifried Edelmann, Amit Verma, Ulrich Steidl
Journal: Blood (2015)
Rituximab-Mediated Inhibition of the Constitutive NIK/IKK/IκB/NF-κB Signaling Pathway in Non-Hodgkin’s Lymphoma (NHL) B-Cell Lines: Role in Chemo-Sensitization.
Authors: Ali R. Jazirehi, Sara Huerta-Yepez, Genhong Cheng, Benjamin Bonavida
Journal: Blood (2004)
Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes
Authors: Meri Kaustio, Emma Haapaniemi, Helka Göös, Timo Hautala, Giljun Park, Jaana Syrjänen, Elisabet Einarsdottir, Biswajyoti Sahu, Sanna Kilpinen, Samuli Rounioja, Christopher L. Fogarty, Virpi Glumoff, Petri Kulmala, Shintaro Katayama, Fitsum Tamene, Luca Trotta, Ekaterina Morgunova, Kaarel Krjutškov, Katariina Nurmi, Kari Eklund, Anssi Lagerstedt, Merja Helminen, Timi Martelius, Satu Mustjoki, Jussi Taipale, Janna Saarela, Juha Kere, Markku Varjosalo, Mikko Seppänen
Journal: Journal of Allergy and Clinical Immunology (2017)
The detection of human papillomavirus–16 in squamous cell carcinoma of the nail unit: A case series
Authors: Emi Dika, Simona Venturoli, Annalisa Patrizi, Bianca Maria Piraccini, Pier Alessandro Fanti, Daniela Barbieri, Martina Nocera, Marco Adriano Chessa, Maria Paola Landini, Michelangelo La Placa
Journal: Journal of the American Academy of Dermatology (2017)
Autologous Ex-Vivo Regulatory T Cells(Tregs) Expansion in Aplastic Anemia for Potential Clinical Use
Authors: Benedetta Costantini, Shahram Kordasti, Seidl Thomas, Smith Alexander, Mian Syed, Aytug Kizilors, Martinez-Llordella Marc, Judith C Marsh, Ghulam J. Mufti
Journal: Blood (2015)
Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents.
Authors: Maria Roussou, Efstathios Kastritis, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Charis Matsouka, Despina Mparmparoussi, Irini Grapsa, Erasmia Psimenou, Dimitra Gika, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood (2009)
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Authors: Khun Visith Keu, Timothy H. Witney, Shahriar Yaghoubi, Jarrett Rosenberg, Anita Kurien, Rachel Magnusson, John Williams, Frezghi Habte, Jamie R. Wagner, Stephen Forman, Christine Brown, Martin Allen-Auerbach, Johannes Czernin, Winson Tang, Michael C. Jensen, Behnam Badie, Sanjiv S. Gambhir
Journal: Science Translational Medicine (2017)

PET gene reporter imaging can be used to monitor the trafficking of therapeutic cytotoxic T cells in glioma patients.
Diagnostic capability of prostate multiparametric magnetic resonance in prediction of cancer and histological grade.
Authors: Jaime Antonio Altamirano, Ivan Federico Pinto, Maria Jesus Quiroz, Jorge Gonzalo Diaz, Mauricio Canals, Roberto Mauricio Vilches, Camilo Sandoval, Alvaro Daniel Vidal, Alejandro Rojas, Cristobal Roman
Journal: Journal of Clinical Oncology (2016)

161 Background: The prostatic multiparametric MRI (mpMRI) can enhance the performance of the prostate core biopsy to detect cancer. The objective of this study is to assess the capability of MpMRI to identify high- and intermediate-risk prostate cancer. Methods: Prospective cohort. MpMRI was performed to patients with TRUS-guided biopsy indication prior to the biopsy. Diffusion, PIRADS, DCE and T2 parameters were observed on the MRI, and the presence of cancer and Gleason score on the biopsy. The results were divided between no cancer, and presence of cancer Gleason 6 or higher. Logistic regression test was performed with a 95% confidence interval. We assigned different values, depending on the importance of each factor, applying binominal regression. Ordinal regression was then performed and Odds ratio calculated. Results: Seventy three patients met the described criteria. Cancer detection rate was 60.27% (44 patients). Seventeen of these patients were Gleason score six. The calculated score, gave 7 points for altered T2, 8 points for altered diffusion and 5 points for altered DCE. With a score of 12 points or more, the calculated sensibility was 84,62% and the specificity was 41.18%. The estimated OR was 1.15 [IC 1-1.38]. We calculated that having one altered parameter, had a probability between 0.17 and 0.25 of having intermediate and high-risk cancer. With more than one altered parameter, the probability was 0.37. One or more altered parameters gives a probability of having Gleason 6 score of 0.20 to 0.25. Conclusions: The MpMRI is a useful tool because it has high correlation with the histological grade, and it´s an excellent test for predicting high- and intermediate-risk prostate cancer when two or more parameters are altered. Based on this findings we strongly suggest TRUS-guided biopsy with an altered MpMRI.
Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.
Authors: Umberto Vitolo, Emanuele Zucca, Maurizio Martelli, Annalisa Chiappella, Ileana Baldi, Monica Balzarotti, Annarita Conconi, Henry Gomez, Armando Lopez-Guillermo, Giovanni Martinelli, Lorella Orsucci, Vincenzo Pavone, Giuseppe Rossi, Sergio Storti, Mary K. Gospodarowicz, Franco Cavalli, Andreas H. Sarris
Journal: Blood (2006)
Granulocyte Transfusion in Febrile Neutropenia
Authors: Gonul Aydogan, Gonca Keskindemirci, Deniz Tugcu, Ferhan Akici, Zafer Salcioglu, Arzu Akcay, Hulya Sen, Muge Gokce, Cengiz Bayram, Ali Aycicek, Nuray Aktay Ayaz
Journal: Blood (2015)
The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Jatin Shah, Joan Blade, Jesus San Miguel, Pieter Sonneveld, Donghan Luo, Keith C Lantz, Colin Lowery, Jean-Luc Harousseau, Robert Z. Orlowski
Journal: Blood (2008)
Ultra-Deep Next-Generation Sequencing (NGS) Detects BCR-ABL1 Kinase Domain Mutations with High Sensitivity and Allows to Monitor the Composition of Distinct Subclones During Tyrosine Kinase Inhibitor Treatment
Authors: Vera Grossmann, Melanie Wild, Susanne Schnittger, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, Alexander Kohlmann
Journal: Blood (2010)
Efficacy of Fludarabine and Cytarabine Combination for Salvage Treatment of Refractory/Relapsed Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Promising Results from a Single Center Experience.
Authors: M. Tassara, F. Ciceri, A. Crotta, J. Peccatori, P. Servida, M. Bregni, M. Bernardi
Journal: Blood (2005)
SNP-Array Profiling Identifies Complex Aberrations and Candidate Genes in Myeloproliferative Neoplasms with Leukemic Transformation.
Authors: Frank Stegelmann, Martin Griesshammer, Karlheinz Holzmann, Frank G Rücker, Carmen Blersch, Susanne Kuhn, Stefanie Schauer, Hartmut Dohner, Konstanze Dohner
Journal: Blood (2009)
Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
Authors: Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Mark van Duin, Sonja Zweegman, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk Kooy, Okke de Weerdt, Monique Minnema, Sarah Lonergan, Antonio Palumbo, Henk M. Lokhorst, Annemiek Broijl, Pieter Sonneveld
Journal: Blood (2016)
Targeting Drug-Resistant Myeloma Cells in an Acidic Milieu by Pim Inhibition
Authors: Shiro Fujii, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Ayako Nakano, Kumiko Kagawa, Ryota Amachi, Keiichiro Watanabe, Masahiro Hiasa, Shuji Ozaki, Toshio Matsumoto, Masahiro Abe
Journal: Blood (2012)
Risk and Cause of Death in 9,563 Patients Diagnosed with Myeloproliferative Neoplasms in Sweden Between 1973 and 2005,
Authors: Malin L Hultcrantz, Sally R Hinchliffe, Sigurdur Y Kristinsson, Therese M-L Andersson, Sandra Eloranta, Åsa Rangert Derolf, Jan Samuelsson, Ola Landgren, Paul W Dickman, Paul Lambert, Magnus Björkholm
Journal: Blood (2011)
Identification of Novel MHC Class I and Class II Epitopes of WT1 Using a Peptide Library Screen.
Authors: Katayoun Rezvani, Stephan Mielke, Yasemin Kilical, Matthias Grube, Hiroshi Fujiwara, Giuseppe Sconocchia, Jongming Lee, Frank El-Ouriaghi, Nancy Hensel, A. John Barrett
Journal: Blood (2005)
Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).
Authors: Jorge Enrique Romaguera, Luis Fayad, Maria Alma Rodriguez, F.B. Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Andre Goy, Andreas H. Sarris, Nam H. Dang, Luhua Wang, Hagop M. Kantarjian, Virginia Beasley, L. Jeffrey Medeiros, Ruth L. Katz, Fernando Cabanillas
Journal: Blood (2006)
HER2 comparison with novel 3-gene marker sets for risk prediction of distant recurrence of breast carcinoma
Authors: J. Alsobrook, P. Hraber, L. Davis, C. Harris, P. Doherty, B. Hall, T. Williams, J. Hozier
Journal: Journal of Clinical Oncology (2006)

20009 Background: The risk of distant recurrence in patients with invasive breast carcinoma (BrCa) is predicted imperfectly by currently used factors (e.g. nuclear grade, hormone receptor status), complicating adjuvant therapy decisions. In an effort to discover biomarkers for recurrence, we retrospectively analyzed BrCa recurrence and tumor gene amplification. Multi-gene marker sets were evaluated for predictive significance and accuracy. Because studies of HER2 as a suitable biomarker report positive and negative results, we compared our marker sets with HER2. Methods: 229 of 723 BrCa patients met inclusion criteria: invasive ductal carcinoma, no isolated local recurrence, minimum 4 years follow-up, and archived specimens adequate for fluorescent in situ hybridization (FISH) assay. Study endpoint was recurrence, or non-recurrence throughout follow-up. FISH was performed on formalin-fixed paraffin sections with probes for previously identified genomic regions. Signals were counted with a Metasystems workstation, and used in a “Prognostic Index” (PI) to categorize recurrence risk. One-sided Fisher’s exact test was used to assess increased incidence of distant recurrence in relation to PI and HER2, and increased incidence of HER2 amplification in relation to PI. Results: Two separate 3-gene marker sets were obtained that predict clinical outcome for hormone receptor + (HR+) and hormone receptor − (HR−) tumors. In HR+ samples a PI based upon regions surrounding CYP24, PDCP6IP, and BIRC5 was the best predictor of recurrence, while for HR- specimens the PI was based on the NR1D1, SMARCE1, and BIRC5 regions. The PIs are significantly associated with recurrence of HR+ and HR− tumors (OR = 9.52, 95% CI &gt; 2.12, p = 0.0024; and OR = 12.3, 95% CI &gt; 1.45, p = 0.0188, respectively). However, tumor HER2 amplification was not prognostic for recurrence (OR = 1.76, 95% CI &gt; 0.77, p = 0.1395). Furthermore, there was no significant association of PI with HER2 status (OR = 1.56, CI &gt; 0.57, p = 0.862). Conclusions: Prognostic Indices based on copy numbers of two 3-gene marker sets significantly predict clinical outcome of stage I-III invasive ductal carcinoma. HER2 amplification, included in our previous whole genome survey but not present in our final marker sets, had no prognostic value. [Table: see text]
High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).
Authors: Sarah Larson, Nicholas Campbell, Dezheng Huo, Andrew Artz, Yanming Zhang, Devika Gajria, Margaret Green, Gamar Rahimova, Howard Weiner, Monica Torres, Olatoyosi Odenike, Lucy A Godley, Elizabeth Shima Rich, Michael Thirman, Richard A. Larson, Wendy Stock
Journal: Blood (2009)
Long-Term Outcome after LACE (Lomustine, Ara-C, Cyclophosphamide, Etoposide) Conditioned Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin’s Lymphoma: A Single Centre Experience.
Authors: Jolanta B. Perz, Chrissy M. Giles, Donald MacDonald, Jane F. Apperley, Edward J. Kanfer
Journal: Blood (2005)
Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy compared with hepatic resection for metastatic colorectal cancer.
Authors: Aaron Udell Blackham, Greg B. Russell, John H. Stewart, Konstantinos Ioannis Votanopoulos, Edward Allen Levine, Perry Shen
Journal: Journal of Clinical Oncology (2012)

630 Background: Surgical resection of peritoneal metastases (PM) from colorectal cancer has been reported to yield outcomes similar to liver resection for hepatic metastases (HM). However recent data suggests PM may have a worse prognosis than other metastatic sites. Methods: A review of metastatic colorectal cancer patients obtained from prospective databases (1992-2010) comparing liver resection for HM to cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for PM. Results: 181 patients underwent hepatic resection and 182 patients underwent CS/HIPEC with a median follow-up of 55 and 106 months respectively. A margin-negative resection was obtained in 168 (93%) hepatic resections, while 89 patients (49%) with PM had complete cytorection of all gross disease (R0/R1). A comparison of these two groups demonstrated significant differences in age, pre-operative chemotherapy and performance status. Disease-free median survival was 15.2 months after hepatic resection and 9.9 months after CS/ HIPEC (p=0.02). The 5-year overall survival (OS) for HM patients was 33% with a median OS of 45.0 months; while 5-year OS was 23% and median OS was 32.3 months for PM patients (p=0.02). In a proportional hazards regression model, performance status and pre-operative chemotherapy had no significant effect on survival, while increased age (p=0.02) and PM (p=0.03) were associated with decreased OS. Postoperative morbidity was 38% versus 51% (p=0.04) and mortality was 3.0% versus 2.3% (p=0.73) in the HM and PM groups, respectively. Conclusions: Disease-free survival and OS are worse for patients who received complete cytoreduction and CS/HIPEC for PM compared to margin-negative liver resection for HM suggesting a more aggressive tumor biology in PM.
Phenotypic Correction of a Mouse Model of Hemophilia B by In Vivo Genetic Correction of the F9 Gene
Authors: Hojun Li, Virginia Haurigot, Yannick Doyon, James Li, Anand Bhagwat, Sunnie Wong, Xavier Anguela, Rajiv Sharma, Lacramioara Ivanciu, Samuel Murphy, Shangzhen Zhou, David Paschon, Edward Rebar, Philip D. Gregory, Michael C. Holmes, Katherine A. High
Journal: Blood (2010)
Systemic Delivery of the Cancer Gene Therapy Biologic, SNS01, Has Significant Anti-Tumoral Activity in a Murine Model of Multiple Myeloma.
Authors: Catherine A Taylor, John A. Lust, Bin Ye, Zhongda Liu, Zhong Sun, Richard S. Dondero, Bruce Galton, Kathleen A. Donovan, John E. Thompson
Journal: Blood (2009)
G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro.
Authors: Heather G. Jorgensen, Mhairi Copland, Elaine K. Allan, Allen C. Eaves, Connie J. Eaves, Xiaoyan Jiang, Tessa L. Holyoake
Journal: Blood (2004)
Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.
Authors: Nicola Gökbuget, Renate Arnold, Angelika Böhme, Rainer Fietkau, Mathias Freund, Arnold Ganser, Michael Kneba, Thomas Lipp, Wolf-Dieter Ludwig, Georg Maschmeyer, Dorle Messerer, Harald Rieder, Eckard Thiel, Dieter Hoelzer
Journal: Blood (2007)
Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology
Authors: Karen L. Posey, Francoise Coustry, Alka C. Veerisetty, Mohammad Hossain, Danielle Gattis, Sheri Booten, Joseph L. Alcorn, Punit P. Seth, Jacqueline T. Hecht
Journal: Molecular Therapy (2017)

Mutations in cartilage oligomeric matrix protein cause pseudoachondroplasia, a severe disproportionate short stature disorder. Mutant cartilage oligomeric matrix protein produces massive intracellular retention of cartilage oligomeric matrix protein, stimulating ER and oxidative stresses and inflammation, culminating in post-natal loss of growth plate chondrocytes, which compromises linear bone growth. Treatments for pseudoachondroplasia are limited because cartilage is relatively avascular and considered inaccessible. Here we report successful delivery and treatment using antisense oligonucleotide technology in our transgenic pseudoachondroplasia mouse model. We demonstrate delivery of human cartilage oligomeric matrix protein-specific antisense oligonucleotides to cartilage and reduction of cartilage oligomeric matrix protein expression, which largely alleviates pseudoachondroplasia growth plate chondrocyte pathology. One antisense oligonucleotide reduced steady-state levels of cartilage oligomeric matrix protein mRNA and dampened intracellular retention of mutant cartilage oligomeric matrix protein, leading to a reduction of inflammatory markers and cell death and partial restoration of proliferation. This novel and exciting work demonstrates that antisense-based therapy is a viable approach for treating pseudoachondroplasia and other human cartilage disorders.
Daclizumab Therapy Improves Outcome in Steroid Refractory Acute Graft Versus Host Disease (aGVHD).
Authors: Richard T. Doocey, Matthew J. Greenwood, Dawn Warkentin, Kevin W. Song, Alan Le, Janet Nitta, Thomas J. Nevill, Michael J. Barnett, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, Stephen H. Nantel, John D. Shepherd, Heather J. Sutherland, Cynthia L. Toze, Clayton A. Smith
Journal: Blood (2004)
Determinants of Platelet Counts in Patients with Chronic Graft Versus Host Disease.
Authors: Drazen Pulanic, David Liewehr, Seth Steinberg, Sandra A. Mitchell, Kristin Baird, Edward W. Cowen, Galen Joe, Kirsten M. Williams, Daniele Avila, Rachel B. Salit, Niveen Atlam, Ashley Carpenter, Fran Hakim, Michael Bishop, Ronald E. Gress, Steven Z. Pavletic
Journal: Blood (2009)
Single Cas9 nickase induced generation of NRAMP1 knockin cattle with reduced off-target effects
Authors: Yuanpeng Gao, Haibo Wu, Yongsheng Wang, Xin Liu, Linlin Chen, Qian Li, Chenchen Cui, Xu Liu, Jingcheng Zhang, Yong Zhang
Journal: Genome biology (2017)

The CRISPR-Cas9 system is a widely utilized platform for transgenic animal production in various species, although its off-target effects should be addressed. Several applications of this tool have been proposed in model animals but remain insufficient for transgenic livestock production.
Let-7a, Mir-17 and Mir-20a Expression Levels in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndromes (MDS) Are Associated with Established Prognostic Factors, Supporting Their Implication in the Pathogenesis of the Disease,
Authors: Christos K Kontos, Vassiliki Pappa, Diamantina Vasilatou, Maria-Angeliki S Pavlou, Frida Kontsioti, Sotirios G Papageorgiou, Panayoula Tsiotra, Christina Economopoulou, Vassiliki Bakou, Efstathios Papageorgiou, Theofanis Economopoulos, John Dervenoulas
Journal: Blood (2011)
Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8–10 Prostate Cancer. Eur Urol 2017;71:907–12
Authors: Christian Daniel Fankhauser, Lorelei A. Mucci, Travis A. Gerke
Journal: European Urology (2017)
Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2017;71:766–73
Authors: Amar U. Kishan, Michael L. Steinberg, Patrick A. Kupelian, Christopher R. King
Journal: European Urology (2017)
Clusters of Acute Respiratory Illness Associated With Human Enterovirus 68-Asia, Europe, and United States, 2008-2010 (Reprinted from MMWR, vol 60, pg 1301-1304, 2011)
Authors: Tadatsugu Imamura, Akira Suzuki, Adam Meijer, Hubert G. M. Niesters, Janette C. Rahamat-Langendoen, Jose Lojo, Richard L. Hodinka, Susan Coffin, Stephen M. Ostroff, Colleen S. Kraft, Georgia. John T. Redd, Dean D. Erdman, Xiaoyan Lu, Mark S. Oberste, Lauren J. Stockman, Gregory L. Armstrong, Lara M. Jacobson, Catherine Y. Yen
Journal: JAMA (2011)
Array-CGH Based Genomic Profiling in B-Cell Chronic Lymphocytic Leukemia Reveals Specific Correlations of Genomic Imbalances and Prognostic Subgroups and Underlines the Consistency of Chromosomal Aberration Patterns within This Disease.
Authors: Carsten Schwaenen, Dirk Kienle, Alexander Krober, Sandra Ruf, Dirk Winkler, Holger Kohlhammer, Hans A. Kestler, Peter Lichter, Swen Wessendorf, Hartmut Dohner, Stephan Stilgenbauer
Journal: Blood (2006)